ロード中...

A phase 1 study of crenigacestat (LY3039478), the Notch inhibitor, in Japanese patients with advanced solid tumors

Background This phase 1, single-center, nonrandomized, single-arm, open-label, dose-escalation study, evaluated the tolerability of crenigacestat, a γ-secretase inhibitor as an oral Notch inhibitor in Japanese patients with advanced solid tumors. Methods The study consisted of 2 dose levels of creni...

詳細記述

保存先:
書誌詳細
出版年:Invest New Drugs
主要な著者: Doi, Toshihiko, Tajimi, Masaomi, Mori, Joji, Asou, Hiroya, Inoue, Koichi, Benhadji, Karim A., Naito, Yoichi
フォーマット: Artigo
言語:Inglês
出版事項: Springer US 2020
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7960611/
https://ncbi.nlm.nih.gov/pubmed/32939607
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-020-01001-5
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!